MedTrace Logo

Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria

NCT02574130 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-04-26

No results posted yet for this study

Summary

The purpose of this study is to determine the cure rate from ventilator-associated pneumonia (VAP) caused by Gram negative bacteria when administering add on nebulized amikacin to intravenous antibiotics compared to intravenous antibiotics alone.

Conditions

  • Pneumonia, Ventilator-Associated

Interventions

DRUG

Amikacin

400 mg, nebulizer, every 12 hours, 10 days

DRUG

Placebo

placebo 4 ml, nebulizer, every 12 hours, 10 days

Sponsors & Collaborators

  • Thammasat University

    lead OTHER

Principal Investigators

  • Pitchayapa Ruchiwit, MD · Thammasat University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02574130 on ClinicalTrials.gov